Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ObsEva SA

www.obseva.com

Latest From ObsEva SA

ObsEva Gives Up On IVF Drug As Phase III Study Fails

Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.

Clinical Trials Companies

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

A second Phase III trial testing relugolix met its primary endpoint, putting Myovant in a tight race with AbbVie to bring the first drug to market for women with uterine fibroids.

Clinical Trials Business Strategies

Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • ObsEva SA
  • Senior Management
  • Ernest Loumaye, MD, PhD, CEO
    Timothy Adams, CFO
    Jean-Pierre Gotteland , PhD, CSO
    Ben T Tan, VP, Commercial & Bus. Dev.
    Elizabeth Garner , MD, CMO
    Wim Souverijns, PhD, Chief Commercial Officer
  • Contact Info
  • ObsEva SA
    Phone: (0)22 552 3840
    Chemin des Aulx 12
    Plan-les-Ouates, 1228
    Switzerland
UsernamePublicRestriction

Register